Diphenyihydantion in Post - Hepretic Neuralgia

Area of Science:

• Neurology
• Dermatology
• Pharmacology

Background:

• Herpes zoster (shingles) can lead to debilitating post-herpetic neuralgia (PHN).
• Effective management of PHN remains a clinical challenge, particularly in older adults.

Purpose of the Study:

• To evaluate the efficacy of diphenylhydantoin in preventing post-herpetic neuralgia.
• To compare the incidence of PHN in patients treated with diphenylhydantoin versus conventional therapies.

Main Methods:

• A study involved 30 patients over 50 years old with herpes zoster, treated with diphenylhydantoin (100 mg twice daily for 10 days).
• A control group of 30 patients received conventional analgesics, antacids, antihistamines, and antibiotics.
• The incidence of post-herpetic neuralgia was compared between the two groups.

Main Results:

• Only 20% of patients in the diphenylhydantoin group developed post-herpetic neuralgia.
• In contrast, 80% of patients in the control group experienced post-herpetic neuralgia.
• Diphenylhydantoin demonstrated a substantial reduction in PHN incidence.

Conclusions:

• Diphenylhydantoin is an effective treatment for reducing the incidence of post-herpetic neuralgia in older patients with herpes zoster.
• This finding suggests a promising therapeutic option for managing shingles complications.